<DOC>
	<DOCNO>NCT02757352</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy study drug know ixekizumab biologic disease modify antirheumatic drug ( bDMARD ) naïve participant nonradiographic axial spondyloarthritis ( nonrad-axSpA ) .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) Participants With Nonradiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Are ambulatory . Diagnosis nonradiographic axial spondyloarthritis ( nraxSpA ) fulfilling 2009 ASAS classification criterion . Have history back pain ≥3 month age onset &lt; 45 year . Have active nraxSpA define BASDAI ≥4 total back pain ≥4 NRS screen baseline . Have objective sign inflammation presence sacroiliitis MRI and/or presence elevate CRP . In past inadequate response least 2 nonsteroidal antiinflammatory drug ( NSAIDS ) duration 4 week tolerate NSAIDS . If take NSAIDS stable dose least 2 week prior randomization . Have history prior therapy axSpA least 12 week prior screen . Have radiographic sacroiliitis fulfilling 1984 modify New York criterion . Have receive prior , currently receive treatment biologics , tumor necrosis factor inhibitor immunomodulatory agent . Have receive live vaccine within 12 week vaccination Bacillus CalmetteGuerin ( BCG ) within past year . Have ongoing serious infection within last 12 week evidence active tuberculosis . Have compromise immune system . Have serious and/or uncontrolled disease . Have either current diagnosis recent history malignant disease . Have major surgery within 8 week baseline , require surgery study . Are pregnant breastfeeding . Have evidence active anterior uveitis ( acute episode ) within last 42 day prior baseline randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ankylose</keyword>
	<keyword>nonradiographic spondyloarthritis</keyword>
</DOC>